275371-94-3

Taspoglutide with -methylalanine in greatly retard degradation by DPP-IV and neutral endopeptidase24.11, respectively (see preceding discussion for exenatide).The phase III trials, which commenced in 2008, arebeing conducted with a zinc-based preparation, prolongingthe duration in a manner similar to zinc-containing insulinpreparations, so that once-weekly injections of 20 to 30 mgwill be possible.

Store at -20°C